THERAPY DOSSIER · th-68e0fe157999

Neuro-Cells, fresh human bone marrow-derived CD34-positive and CD105-positive stem cells

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31100652 ↗2019Reported benefit

Standardized human bone marrow-derived stem cells infusion improves survival and recovery in a rat model of spinal cord injury.

RatSpinal cord injuryCompressionNude (immunodeficient, T-cell deficient) ratsmaleintrathecal400,000 fresh human bone marrow-derived CD34-positive cells…One day after balloon compression

Model: Balloon compression of the spinal cord

A single intrathecal Neuro-Cells infusion improved locomotor recovery and reduced adverse events over 5 weeks and reduced astrogliosis and apoptosis at day 4 but not at day 56.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…